346 related articles for article (PubMed ID: 30006816)
1. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.
Juncadella A; Papamichael K; Vaughn BP; Cheifetz AS
Dig Dis Sci; 2018 Nov; 63(11):3067-3073. PubMed ID: 30006816
[TBL] [Abstract][Full Text] [Related]
2. Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease.
Papamichael K; Rakowsky S; Rivera C; Cheifetz AS; Osterman MT
Inflamm Bowel Dis; 2018 Sep; 24(10):2266-2271. PubMed ID: 29718327
[TBL] [Abstract][Full Text] [Related]
3. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
Ungaro RC; Yarur A; Jossen J; Phan BL; Chefitz E; Sehgal P; Kamal K; Bruss A; Beniwal-Patel P; Fox C; Patel A; Bahur B; Jain A; Stein D; Naik S; Dubinsky MC
J Crohns Colitis; 2019 Aug; 13(8):963-969. PubMed ID: 31087100
[TBL] [Abstract][Full Text] [Related]
4. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
[TBL] [Abstract][Full Text] [Related]
5. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
[TBL] [Abstract][Full Text] [Related]
6. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study.
Kamat N; Kedia S; Ghoshal UC; Nehra A; Makharia G; Sood A; Midha V; Gupta V; Choudhuri G; Ahuja V
Indian J Gastroenterol; 2019 Feb; 38(1):44-54. PubMed ID: 30645725
[TBL] [Abstract][Full Text] [Related]
8. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
[TBL] [Abstract][Full Text] [Related]
9. Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis.
Yarur AJ; Jain A; Hauenstein SI; Quintero MA; Barkin JS; Deshpande AR; Sussman DA; Singh S; Abreu MT
Inflamm Bowel Dis; 2016 Feb; 22(2):409-15. PubMed ID: 26752470
[TBL] [Abstract][Full Text] [Related]
10. Higher Maintenance Adalimumab Trough Levels are Associated With Achievement of Advanced Remission Targets in Patients With Inflammatory Bowel Disease.
Ritter E; Hirsch A; Isakov NF; Ron Y; Cohen NA; Maharshak N
J Clin Gastroenterol; 2021 Oct; 55(9):810-814. PubMed ID: 33060434
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
[TBL] [Abstract][Full Text] [Related]
12. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.
Shinzaki S; Matsuoka K; Tanaka H; Takeshima F; Kato S; Torisu T; Ohta Y; Watanabe K; Nakamura S; Yoshimura N; Kobayashi T; Shiotani A; Hirai F; Hiraoka S; Watanabe M; Matsuura M; Nishimoto S; Mizuno S; Iijima H; Takehara T; Naka T; Kanai T; Matsumoto T
J Gastroenterol; 2021 Jun; 56(6):560-569. PubMed ID: 33942166
[TBL] [Abstract][Full Text] [Related]
13. Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice.
Aguas Peris M; Bosó V; Navarro B; Marqués-Miñana MR; Bastida G; Beltrán B; Iborra M; Sáez-González E; Monte-Boquet E; Poveda-Andrés JL; Nos P
Inflamm Bowel Dis; 2017 Aug; 23(8):1454-1460. PubMed ID: 28708805
[TBL] [Abstract][Full Text] [Related]
14. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
[TBL] [Abstract][Full Text] [Related]
15. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB
Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
[TBL] [Abstract][Full Text] [Related]
16. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.
Solem CA; Loftus EV; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
Inflamm Bowel Dis; 2005 Aug; 11(8):707-12. PubMed ID: 16043984
[TBL] [Abstract][Full Text] [Related]
17. Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases.
Molander P; Kemppainen H; Ilus T; Sipponen T
Scand J Gastroenterol; 2020 Jan; 55(1):34-40. PubMed ID: 31841064
[No Abstract] [Full Text] [Related]
18. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
19. Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.
Hanžel J; Sever N; Ferkolj I; Štabuc B; Smrekar N; Kurent T; Koželj M; Novak G; Compernolle G; Tops S; Gils A; Drobne D
United European Gastroenterol J; 2019 Jul; 7(6):741-749. PubMed ID: 31316778
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide.
Lazzerini M; Villanacci V; Pellegrin MC; Martelossi S; Magazzù G; Pellegrino S; Lucanto MC; Barabino A; Calvi A; Arrigo S; Lionetti P; Fontana M; Zuin G; Maggiore G; Bramuzzo M; Maschio M; Salemme M; Manenti S; Lorenzi L; Decorti G; Montico M; Ventura A
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1382-1389.e1. PubMed ID: 28286192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
